![\"Type](\"http:\/\/blueheronhealthnews.com\/site\/wp-content\/uploads\/2015\/11\/Diabetest_72052601_s-2015.jpg\")
Virtually all prescription drugs carry a risk of side effects, which can range from minor nuisances like an itchy rash, to severely debilitating or fatal consequences.<\/p>\nVirtually all prescription drugs carry a risk of side effects, which can range from minor nuisances like an itchy rash, to severely debilitating or fatal consequences.<\/p>\n
Sometimes, these drugs even carry a risk of worsening the very problem they are designed and prescribed to treat, leaving a person in worse shape than they already were before taking the medication.<\/p>\n
A recent study published in the Journal of Biological Chemistry, highlights one such case. It looked at a potential for disaster involving a certain class of drug, used to treat type 2 diabetes. <\/p>\n
Scientists looking at the newly developing trend of using a glucagon-like peptide, or GLP-1, to treat type 2 diabetes are very frustrated at a glaring risk associated with it.<\/p>\n
GLP-1 is a natural hormone the body produces after eating that stimulates the release of insulin. Scientists have been able to isolate and reproduce this hormone. However, GLP-1 in its natural form doesn\u2019t last long when it is injected. <\/p>\n
So researchers came up with a synthetic form of it that lasts longer in the body. These are called GLP-1 mimetics because they mimic the effect of the hormone in the body.<\/p>\n
Here is where it gets confusing \u2013 and potentially very dangerous. The drugs are designed to prevent the release of sugars from the liver into the blood stream. But there is a dangerous series of events possible because of GLP-1\u2019s interaction with a molecule in the body called RAMP2. <\/p>\n
RAMP2 is present in most people\u2019s bodies, but in unpredictable amounts. In fact, not much is even known about it other than it is necessary for preventing GLP-1 from binding with glucagon receptors. When that bond happens, it tells the liver to release sugar.<\/p>\n
The problem arises for diabetics when RAMP2 is either missing or insufficient. Then it can\u2019t block the glucagon receptors, and the GLP-1 binds with them. This stimulates the liver to release sugar, which is the opposite of what should be happening for a type 2 diabetic.<\/p>\n
It\u2019s not as critical with natural GLP-1 because of the extremely brief time it is active in the body. But GLP-1 mimetics last much longer and have an exponentially higher opportunity to find and bind with the glucagon receptors.<\/p>\n
Not enough is even known about the interactions between RAMP2, GLP-1, and glucagon to be able to say definitively what the actual risk is. Drug makers would take this as ambiguous at best and say until actual bad events come in, and with enough frequency, no news must be good news. <\/p>\n
Critics say this is a dangerous gamble to take with people\u2019s lives, and to not inform them of the risk is incredibly irresponsible.<\/p>\n
Either way, it is clear that reversing type 2 diabetes naturally, without medications, is the only guaranteed way to avoid side effects. No meds, no problems.<\/p>\n